Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.


We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Reaxense helps in synthesizing and delivering these compounds.


The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.


We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.


Several key aspects differentiate our library:


  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.

  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.

  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.

  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.


PARTNER
Receptor.AI
 
UPACC
P37058

UPID:
DHB3_HUMAN

ALTERNATIVE NAMES:
Estradiol 17-beta-dehydrogenase 2; Short chain dehydrogenase/reductase family 12C member 2; Testicular 17-beta-hydroxysteroid dehydrogenase; Testosterone 17-beta-dehydrogenase 3

ALTERNATIVE UPACC:
P37058; Q5U0Q6

BACKGROUND:
The enzyme 17-beta-hydroxysteroid dehydrogenase type 3, also known as Testosterone 17-beta-dehydrogenase 3, is crucial for converting androstenedione to testosterone. This reaction is essential for male sexual development and involves the use of NADPH. The enzyme's ability to accept various androgens as substrates highlights its significant role in androgen biosynthesis.

THERAPEUTIC SIGNIFICANCE:
Given its central role in androgen biosynthesis, mutations affecting 17-beta-hydroxysteroid dehydrogenase type 3 are implicated in Male pseudohermaphroditism with gynecomastia. Exploring this enzyme's mechanisms offers a promising avenue for developing targeted therapies to correct hormonal imbalances.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.